FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199214966> ?p ?o ?g. }

• W3199214966 endingPage "288" @default.
• W3199214966 startingPage "248" @default.
• W3199214966 abstract "•All studies compared Bamlanivimab monotherapy vs. control group.•A total of 8 studies comprising of 13,573 adult patients with COVID-19 were included.•Outcomes suggested Bamlanivimab improved hospitalization and mortality rates. The coronavirus disease 2019 (COVID-19) pandemic has spread globally and poses a serious threat to the world. As of August 9, 2021, there were over 200 million COVID-19 cases and 4 million deaths. The clinical manifestations of COVID-19 range from mild to severe, the incidence of illness and mortality is high in some vulnerable subgroup of patients. Until now, treatment option for patients to prevent progression to severe COVID-19 is limited. Although, vaccination is considered as an effective method to stop the spread of the COVID-19 pandemic, the newly emerged SARS-CoV-2 variants have led to breakthrough infections after completion of vaccination regimen.1Duerr R. Dimartino D. Marier C. et al.Dominance of alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City.J Clin Investig. 2021; 131 (152702): e152702Google Scholar The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attaches to host cells by binding its spike protein to angiotensin-converting enzyme 2 (ACE2) receptors on target cells.2Hoffmann M. Kleine-Weber H. Schroeder S. et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell. 2020; 181 (e8): 271-280Google Scholar Bamlanivimab (also knowns as LY-CoV555 or LY3819253), a recombinant human IgG1 monoclonal antibody, binds to the receptor binding domain of the spike protein of SARS-CoV-2 and blocks viral entry into host cells. Bamlanivimab(BAM) was granted emergency use authorization by the Food and Drug Administration (FDA) in November 2020.[3]Nathan R. Shawa I. De La Torre I. et al.A narrative review of the clinical practicalities of Bamlanivimab and Etesevimab antibody therapies for SARS-CoV-2.Infect Dis Ther. 2021; : 1-15Google Scholar Currently, there were a few studies that evaluated the effect of BAM on clinical outcomes in patients with mild-to-moderate COVID-19. Thus, we aim to perform a systematic review and meta-analysis of the available evidence to investigate the efficacy of BAM in COVID‐19. An electronic search of the PubMed, Embase, and Cochrane Library databases was conducted from December 1 2019, to August 9 2021, with no language restrictions. The following key words and/or medical subject heading terms searched were used: (“COVID-19″ or “novel coronavirus” or “2019-nCoV” or “coronavirus disease 2019″ or “SARS-CoV-2″) AND (“Bamlanivimab” or “LY3819253” or “LY-CoV555”). A manual search of possible articles that were relevant to the topic were carried out. “PROSPERO (International Prospective Register of Systematic Reviews) database” registration was done with study number as CRD42021274064. The inclusion criteria in our meta-analysis were as follows: (1) Patients with confirmed COVID-19; (2) reported information of comparison of clinical outcomes between BAM treatment (administered alone) and various control groups (no treatment, usual care according to the hospital guidelines, NIH guidelines). Studies were excluded if they were (1) case reports, conference abstracts, non-clinical studies, editorials and reviews; and (2) duplicated publications. All data from studies were extracted by independent investigators (GA and YW) onto prespecified. Any discrepancies were resolved through discussion in group conference. We also extracted baseline information of name of the first author, study design, country, the participants, number of participants, demographics data (mean/median age, male gender), dose of Bamlanivimab used, outcomes (mortality, hospitalizations, deterioration and progression to the complications). The quality of randomized controlled studies (RCTs) was evaluated using the Jadad scale. The quality of observational studies was assessed using a nine-item Newcastle-Ottawa Quality scale. High-quality studies were defined as a study with a Jadad score of ≥ 2 (maximum, 5), or a modified Newcastle-Ottawa score (NOS) of ≥ 6 (maximum, 9). The analysis was done using Review Manager and Stata software version 15.1. Reported odd ratios (ORs) and 95% CIs were extracted from each study. We selected OR as an effect estimate. The heterogeneity of outcomes was calculated using Cochran's Q test and the I2 statistic. The I2 value of 25%, 50%, and 75% represented low, moderate, and high degrees of heterogeneity, respectively. If I2 ≤ 50%, the meta-analysis was performed using the fixed effect model (Mantel-Haenszel). If I2 > 50%, the random-effect model (DerSimonian and Laird) was preferred. Sensitivity or subgroup analyses were performed to identify potential sources of heterogeneity. Sensitivity analysis was performed to evaluate the stability of the results by sequentially omitting one study at a time. P < 0.05 was considered to be statistically significant. The search strategy yielded 263 potentially eligible literatures. Among them, 47 literatures were excluded due to duplicated searches. 168 studies were subsequently screened and regarded as absolute irrelevant studies by examining titles and abstracts. 48 studies were identified for full-text review and 40 studies were excluded because they had no comparison groups between Bamlanivimab treatment and control or outcomes were not available. A total of 8 studies4Alam M.M. Mahmud S. Aggarwal S. et al.Clinical impact of the early use of monoclonal antibody LY-CoV555 (Bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study.Cureus. 2021; 13: e14933Google Scholar–11Kumar R.N. Wu E.L. Stosor V. et al.Real-world experience of Bamlanivimab for COVID-19: a case-control study.Clin Infect Dis. 2021; (ciab305)https://doi.org/10.1093/cid/Google Scholar comprising of 13,573 adult patients with COVID-19, including 4191 in the BAM (administered alone) and 9382 in the control group arm, were included in this meta-analysis. The study characteristics of the included RCT, cohort studies and case-controls are shown in Table 1. All studies were from America. Four studies were retrospective cohort, two studies were case-control and only one study was RCT. Most studies included mild to moderate COVID-19 nonhospitalized patient and used a dosage of 700 to 7000 mg infusion of Bamlanivimab. All of the eligible studies were published in 2021 with different sample patient sizes that ranged from 46 to 6117 patients with COVID-19. The details of quality assessment are presented in the Supplemental Tables 1 and 2. All studies included in our meta-analysis were considered as high quality (RCT with a Jadad score of ≥ 2 and observational studies with a modified NOS score of ≥ 6).Table 1Characteristics of included studies.StudyCountryStudy designStudy populationDefinition of severity usedDose of bamlanivimabSample sizeBamlanivimab groupControl groupAgeMale (%)AgeMale (%)Alam4Alam M.M. Mahmud S. Aggarwal S. et al.Clinical impact of the early use of monoclonal antibody LY-CoV555 (Bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study.Cureus. 2021; 13: e14933Google ScholarAmericaCase-controlMild-to-moderate COVID-19 in nursing homes and long-term care facilitieRequiring mechanical ventilation700 mg24681.42 ± 0.6882 (51.2)84.42 ± 0.8935 (40.7)Bariola[5]Bariola J.R. McCreary E.K. Wadas R.J. et al.Impact of Bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome coronavirus 2 infection.Open Forum Infect Dis. 2021; 8: ofab254Google ScholarAmericaRetrospective cohortMild to moderate COVID-19 nonhospitalized patientNR700 mg139267.3 ± 13108 (46.6)67.1 ± 13.4510 (44)Corwin[6]Corwin D.S. Ender P.T. Sahu N. et al.The efficacy of Bamlanivimab in reducing emergency department visits and hospitalizations in a real-world setting.Open Forum Infect Dis. 2021; 8: ofab305Google ScholarAmericaRetrospective cohortOutpatients with mild to moderate COVID-19NR700 mg611762.6 ± 15.6352 (45.1)56.7 ± 2.02309 (43.3)Destache7Destache C.J. Aurit S.J. Schmidt D. Peet Erkes L. Tierney M. Vivekanandan R Bamlanivimab use in mild-to-moderate COVID-19 disease: a matched cohort design.Pharmacotherapy. 2021; (10.1002/phar.2613)Google ScholarAmericaRetrospective cohortMild to moderate COVID-19 nonhospitalized patientNRNR23472 (65–80)55 (47.0)72 (65–80)55 (47.0)Ganesh[8]Ganesh R. Pawlowski C. O'Horo J.C. et al.Association of intravenous Bamlanivimab use with reduced hospitalization, intensive care unit admission, and mortality in patients with mild to moderate COVID-19.medRxiv. 2021; (10.1101/2021.05.23.21257670)Google ScholarAmericaRetrospective cohortMild to moderate COVID-19 do not hospitalizeICU admissionsSingle-dose bamlanivimab infusion467063 (52,71)1183 (50.7)63(52,72)1181 (50.6)Gottlieb9Gottlieb R.L. Nirula A. Chen P. et al.Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.JAMA. 2021; 325: 632-644Google ScholarAmericaRCTMild-to-moderate COVID-19 nonhospitalized patientNR700 mg, 2800 mg, 7000 mg46539 (31–58)38 (37.6)46 (35–57)71 (45.5)Karr[10]Karr E. Chung T. Burtson K. Markert R. Kelly D. Bamlanivimab use in a military treatment facility.Mil Med. 2021; (usab188)https://doi.org/10.1093/milmed/Google ScholarAmericaRetrospective cohortMild-to-moderate COVID-19 nonhospitalized patientNR700 mg466926 (65)693 (50)Kumar11Kumar R.N. Wu E.L. Stosor V. et al.Real-world experience of Bamlanivimab for COVID-19: a case-control study.Clin Infect Dis. 2021; (ciab305)https://doi.org/10.1093/cid/Google ScholarAmericaCase-controlInpatient and outpatientICU admissions700 mg40366 (57–74)115 (52.8)62 (50–72)95 (51.4)RCT: randomized controlled study; ICU: intensive care unit; NR: not reported. Open table in a new tab RCT: randomized controlled study; ICU: intensive care unit; NR: not reported. The meta-analysis showed the overall mortality was lower in the BAM group compared to control group (OR = 0.27, 95%CI: 0.15, 0.49, P < 0.0001, I2 = 0%) (Fig. 1A). Moreover, BAM treatment were associated with lower risk of hospitalization (OR = 0.60, 95%CI: 0.49 to 0.73, P < 0.00001; I2 = 31%) (Fig. 1B) and developing severe COVID-19 disease (OR = 0.43, 95%CI: 0.23 to 0.81, P = 0.008; I2 = 0%) (Fig. 1C). Pooled analysis of adjusted results revealed that BAM group had a lower risk of mortality (OR = 0.49, 95%CI: 0.27 to 0.89, P = 0.019; I2 = 0%) (Fig. 1D) and hospitalization compared with control group (OR = 0.55, 95%CI: 0.44 to 0.67, P < 0.001; I2 = 0%) (Fig. 1E). In addition, sensitivity analyses by excluding each study at a time did not significantly alter the overall results.Figure. 1AAssociation between Bamlanivimab treatment and mortalityShow full captionFigure. 1B Association between Bamlanivimab treatment and hospitalizationFigure. 1C Association between Bamlanivimab treatment and developing severe COVID-19Figure. 1D Pooled analysis of adjusted results of association between Bamlanivimab treatment and mortalityFigure. 1E Pooled analysis of adjusted results of association between Bamlanivimab treatment and hospitalizationView Large Image Figure ViewerDownload Hi-res image Download (PPT) Figure. 1B Association between Bamlanivimab treatment and hospitalization Figure. 1C Association between Bamlanivimab treatment and developing severe COVID-19 Figure. 1D Pooled analysis of adjusted results of association between Bamlanivimab treatment and mortality Figure. 1E Pooled analysis of adjusted results of association between Bamlanivimab treatment and hospitalization COVID-19 remains a public health emergency. Although people have taken many measures to control the virus, the treatment of COVID-19 remains a challenge. Until now, vaccines are still the primary option for COVID-19 prevention.12Krammer F. SARS-CoV-2 vaccines in development.Nature. 2020; 586: 516-527Google Scholar Unlike vaccine-derived immunity that develops over time, the use of neutralizing monoclonal antibodies is an immediate and passive immunotherapy. In the current meta-analysis, our results demonstrated that patients received BAM treatment had a better outcome in hospitalization and mortality. With limited therapeutic options for COVID-19, BAM provide an effective treatment option. Prevention of hospitalization is an important part of COVID-19 management. High patient volumes in the hospital from COVID-19 strain medical resources and supplies. The shortage of personal protective equipment and air isolation wards will bring greater risks to health care workers. As for mild-to-moderate COVID-19, treatments administered in outpatient is a more reasonable approach to preserver hospital supplies and reduce overcrowding. Our study affirmed the efficacy of BAM in the treatment of mild-to-moderate COVID-19, which was consistent with previous clinical trials (BLAZE-1 and −2).9Gottlieb R.L. Nirula A. Chen P. et al.Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial.JAMA. 2021; 325: 632-644Google Scholar,13Cohen M.S. Nirula A. Mulligan M.J. et al.Effect of Bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial.JAMA. 2021; 326: 46-55Google Scholar Before monoclonal antibodies treatment, there was no strategies to reduce the rates of hospitalization or death in outpatients with COVID-19. SARS-CoV-2 infection is mediated by the interaction between the viral spike and the ACE2 receptors. BAM can specifically block this event. With the evolution of SARS-CoV-2 spike protein, the effect of monoclonal antibody therapy may be affected.14Focosi D. Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based COVID-19 therapeutics and vaccines.Rev Med Virol. 2021; (10.1002/rmv.2231)Google Scholar Due to the evolution of SARS-CoV-2 variants, the emergency use authorization (EUA) for Bamlanivimab monotherapy was rescinded by the FDA on April 16, 2021. Another dual monoclonal antibody treatment, Bamlanivimab plus Etesevimab remains in place.[15]Dougan M. Nirula A. Azizad M. et al.Bamlanivimab plus Etesevimab in mild or moderate COVID-19.N Engl J Med. 2021; (10.1056/NEJMoa2102685)Google Scholar Despite this, the results of this study indicated that treatment with neutralizing antibody was an effective way to mitigate the current COVID-19 pandemic. Several limitations of our study should be noted. Most of the studies included were retrospective in design and had relatively small sample size, which were subject to potential confounders that may weaken the overall results. Moreover, all studies were conducted in America, which may not provide sufficient statistical power to explore accurate correlations. Furthermore, lack of data of individual patient, it is uncertain which patients will benefit most when treated with BAM. Therefore, large clinical RCTs are needed to overcome these limitations Despite these limitations, there were advantages of our meta-analysis. First, to our best knowledge, this is the first meta-analysis assess the clinical impact of Bamlanivimab monoclonal antibody monotherapy on mortality and disease severity in patients with COVID-19. In addition, the heterogeneity across the studies was low, which enhances the reliability of our results. In conclusion, our meta-analysis provide evidence that BAM is effective in the treatment in COVID-19 patients. There is an urgent need for well-designed randomized trials to determine the effectiveness and safety of BAM in severe COVID-19. Download .docx (.04 MB) Help with docx files" @default.
• W3199214966 created "2021-09-27" @default.
• W3199214966 creator A5015376693 @default.
• W3199214966 creator A5044066131 @default.
• W3199214966 creator A5044915303 @default.
• W3199214966 creator A5046131968 @default.
• W3199214966 creator A5058671625 @default.
• W3199214966 date "2022-02-01" @default.
• W3199214966 modified "2023-10-18" @default.
• W3199214966 title "Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis" @default.
• W3199214966 cites W3009912996 @default.
• W3199214966 cites W3087924281 @default.
• W3199214966 cites W3125712166 @default.
• W3199214966 cites W3137152384 @default.
• W3199214966 cites W3153590519 @default.
• W3199214966 cites W3161496725 @default.
• W3199214966 cites W3162448478 @default.
• W3199214966 cites W3164832774 @default.
• W3199214966 cites W3169109379 @default.
• W3199214966 cites W3180923996 @default.
• W3199214966 cites W3186303569 @default.
• W3199214966 cites W3191934781 @default.
• W3199214966 cites W3192451245 @default.
• W3199214966 cites W3194422471 @default.
• W3199214966 cites W4212988737 @default.
• W3199214966 doi "https://doi.org/10.1016/j.jinf.2021.09.003" @default.
• W3199214966 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8438996" @default.
• W3199214966 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34534563" @default.
• W3199214966 hasPublicationYear "2022" @default.
• W3199214966 type Work @default.
• W3199214966 sameAs 3199214966 @default.
• W3199214966 citedByCount "6" @default.
• W3199214966 countsByYear W31992149662022 @default.
• W3199214966 countsByYear W31992149662023 @default.
• W3199214966 crossrefType "journal-article" @default.
• W3199214966 hasAuthorship W3199214966A5015376693 @default.
• W3199214966 hasAuthorship W3199214966A5044066131 @default.
• W3199214966 hasAuthorship W3199214966A5044915303 @default.
• W3199214966 hasAuthorship W3199214966A5046131968 @default.
• W3199214966 hasAuthorship W3199214966A5058671625 @default.
• W3199214966 hasBestOaLocation W31992149661 @default.
• W3199214966 hasConcept C116675565 @default.
• W3199214966 hasConcept C126322002 @default.
• W3199214966 hasConcept C159047783 @default.
• W3199214966 hasConcept C177713679 @default.
• W3199214966 hasConcept C2778137277 @default.
• W3199214966 hasConcept C2779134260 @default.
• W3199214966 hasConcept C2779473830 @default.
• W3199214966 hasConcept C3006700255 @default.
• W3199214966 hasConcept C3007834351 @default.
• W3199214966 hasConcept C3008058167 @default.
• W3199214966 hasConcept C524204448 @default.
• W3199214966 hasConcept C55493867 @default.
• W3199214966 hasConcept C71924100 @default.
• W3199214966 hasConcept C86803240 @default.
• W3199214966 hasConcept C95190672 @default.
• W3199214966 hasConceptScore W3199214966C116675565 @default.
• W3199214966 hasConceptScore W3199214966C126322002 @default.
• W3199214966 hasConceptScore W3199214966C159047783 @default.
• W3199214966 hasConceptScore W3199214966C177713679 @default.
• W3199214966 hasConceptScore W3199214966C2778137277 @default.
• W3199214966 hasConceptScore W3199214966C2779134260 @default.
• W3199214966 hasConceptScore W3199214966C2779473830 @default.
• W3199214966 hasConceptScore W3199214966C3006700255 @default.
• W3199214966 hasConceptScore W3199214966C3007834351 @default.
• W3199214966 hasConceptScore W3199214966C3008058167 @default.
• W3199214966 hasConceptScore W3199214966C524204448 @default.
• W3199214966 hasConceptScore W3199214966C55493867 @default.
• W3199214966 hasConceptScore W3199214966C71924100 @default.
• W3199214966 hasConceptScore W3199214966C86803240 @default.
• W3199214966 hasConceptScore W3199214966C95190672 @default.
• W3199214966 hasIssue "2" @default.
• W3199214966 hasLocation W31992149661 @default.
• W3199214966 hasLocation W31992149662 @default.
• W3199214966 hasLocation W31992149663 @default.
• W3199214966 hasOpenAccess W3199214966 @default.
• W3199214966 hasPrimaryLocation W31992149661 @default.
• W3199214966 hasRelatedWork W3003901880 @default.
• W3199214966 hasRelatedWork W3004511262 @default.
• W3199214966 hasRelatedWork W3005417802 @default.
• W3199214966 hasRelatedWork W3007868867 @default.
• W3199214966 hasRelatedWork W3009669391 @default.
• W3199214966 hasRelatedWork W3020699490 @default.
• W3199214966 hasRelatedWork W3036314732 @default.
• W3199214966 hasRelatedWork W3043486364 @default.
• W3199214966 hasRelatedWork W3084498529 @default.
• W3199214966 hasRelatedWork W3127156785 @default.
• W3199214966 hasVolume "84" @default.
• W3199214966 isParatext "false" @default.
• W3199214966 isRetracted "false" @default.
• W3199214966 magId "3199214966" @default.
• W3199214966 workType "article" @default.